Opko Health CEO Acquires $924,075 in Stock (OPK)

Opko Health (NYSE:OPK) CEO Phillip Md Et Al Frost purchased 92,500 shares of the stock in a transaction that occurred on Wednesday, December 31st. The stock was purchased at an average price of $9.99 per share, with a total value of $924,075.00. Following the completion of the purchase, the chief executive officer now directly owns 2,012,377 shares of the company’s stock, valued at approximately $20,103,646. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Phillip Md Et Al Frost also recently made the following trade(s):

  • On Tuesday, December 23rd, Phillip Md Et Al Frost purchased 40,000 shares of Opko Health stock. The shares were purchased at an average cost of $9.46 per share, for a total transaction of $378,400.00.
  • On Monday, December 22nd, Phillip Md Et Al Frost purchased 10,000 shares of Opko Health stock. The shares were purchased at an average cost of $9.79 per share, for a total transaction of $97,900.00.

Shares of Opko Health (NYSE:OPK) traded up 0.43% on Friday, hitting $10.0325. The stock had a trading volume of 211,214 shares. Opko Health has a one year low of $7.32 and a one year high of $10.25. The stock’s 50-day moving average is $8.72 and its 200-day moving average is $8.70. The company’s market cap is $4.356 billion.

Opko Health (NYSE:OPK) last released its earnings data on Friday, November 7th. The company reported ($0.11) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.07) by $0.04. The company had revenue of $19.80 million for the quarter, compared to the consensus estimate of $25.20 million. Analysts expect that Opko Health will post $-0.35 EPS for the current fiscal year.

Separately, analysts at Oppenheimer reiterated a “positive” rating on shares of Opko Health in a research note on Tuesday, December 16th. They now have a $12.00 price target on the stock. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $10.90.

OPKO Health, Inc (NYSE:OPK) is a multi-national biopharmaceutical and diagnostics company.

Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with Analyst Ratings Network's FREE daily email newsletter.

Latest News

Instacart the Grocery Delivery Startup Raises $210 Million
Instacart the Grocery Delivery Startup Raises $210 Million
China Will Relax Regulations on Banks Renminbi Trading
China Will Relax Regulations on Banks Renminbi Trading
Subway in Safety Scandal in China over Food
Subway in Safety Scandal in China over Food
UPS and FedEx Make Improvements During Holiday Season
UPS and FedEx Make Improvements During Holiday Season
MasterCard Spending Report for Holidays Shows Weak Electronics
MasterCard Spending Report for Holidays Shows Weak Electronics
Gift Cards Have Become Hugely Popular, but Have Risks
Gift Cards Have Become Hugely Popular, but Have Risks


Leave a Reply

Advertisement
Advertisement
© 2006-2015 Leoncheng.